Summary
Global Markets Direct’s, ‘NicOx S.A. - Product Pipeline Review - 2016’, provides an overview of the NicOx S.A.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by NicOx S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of NicOx S.A.
- The report provides overview of NicOx S.A. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses NicOx S.A.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features NicOx S.A.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate NicOx S.A.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for NicOx S.A.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding NicOx S.A.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
NicOx S.A. Snapshot 6
NicOx S.A. Overview 6
Key Information 6
Key Facts 6
NicOx S.A. - Research and Development Overview 7
Key Therapeutic Areas 7
NicOx S.A. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
NicOx S.A. - Pipeline Products Glance 14
NicOx S.A. - Late Stage Pipeline Products 14
Pre-Registration Products/Combination Treatment Modalities 14
Filing rejected/Withdrawn Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
NicOx S.A. - Clinical Stage Pipeline Products 17
Phase I Products/Combination Treatment Modalities 17
NicOx S.A. - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
NicOx S.A. - Drug Profiles 19
cetirizine hydrochloride 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
naproxcinod 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
azithromycin 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
bromfenac sodium 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
fluticasone propionate 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
cerdulatinib 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
ISV-405 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
NCX-1021 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
NCX-1653 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
NCX-250 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
NCX-422 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
NCX-429 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
NCX-434 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
NCX-466 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
NCX-470 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
NCX-667 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
NicOx S.A. - Pipeline Analysis 38
NicOx S.A. - Pipeline Products by Target 38
NicOx S.A. - Pipeline Products by Route of Administration 40
NicOx S.A. - Pipeline Products by Molecule Type 41
NicOx S.A. - Pipeline Products by Mechanism of Action 42
NicOx S.A. - Recent Pipeline Updates 44
NicOx S.A. - Dormant Projects 56
NicOx S.A. - Discontinued Pipeline Products 57
Discontinued Pipeline Product Profiles 57
naproxcinod 57
NCX-1000 57
NCX-1236 57
NCX-226 57
NCX-285 58
NCX-6560 58
NicOx S.A. - Locations And Subsidiaries 59
Head Office 59
Other Locations & Subsidiaries 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 60
Disclaimer 61
List of Tables
NicOx S.A., Key Information 6
NicOx S.A., Key Facts 6
NicOx S.A. - Pipeline by Indication, 2016 9
NicOx S.A. - Pipeline by Stage of Development, 2016 10
NicOx S.A. - Monotherapy Products in Pipeline, 2016 11
NicOx S.A. - Partnered Products in Pipeline, 2016 12
NicOx S.A. - Partnered Products/ Combination Treatment Modalities, 2016 13
NicOx S.A. - Pre-Registration, 2016 14
NicOx S.A. - Filing rejected/Withdrawn, 2016 15
NicOx S.A. - Phase III, 2016 16
NicOx S.A. - Phase I, 2016 17
NicOx S.A. - Preclinical, 2016 18
NicOx S.A. - Pipeline by Target, 2016 39
NicOx S.A. - Pipeline by Route of Administration, 2016 40
NicOx S.A. - Pipeline by Molecule Type, 2016 41
NicOx S.A. - Pipeline Products by Mechanism of Action, 2016 43
NicOx S.A. - Recent Pipeline Updates, 2016 44
NicOx S.A. - Dormant Developmental Projects,2016 56
NicOx S.A. - Discontinued Pipeline Products, 2016 57
NicOx S.A., Subsidiaries 59
List of Figures
NicOx S.A. - Pipeline by Top 10 Indication, 2016 8
NicOx S.A. - Pipeline by Stage of Development, 2016 10
NicOx S.A. - Monotherapy Products in Pipeline, 2016 11
NicOx S.A. - Partnered Products in Pipeline, 2016 12
NicOx S.A. - Pipeline by Top 10 Target, 2016 38
NicOx S.A. - Pipeline by Route of Administration, 2016 40
NicOx S.A. - Pipeline by Molecule Type, 2016 41
NicOx S.A. - Pipeline Products by Top 10 Mechanism of Action, 2016 42
